☆ 4.8 News Item

Nature does things well

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Summary: In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Tyler N. Starr et al.

Summary: Research has found that mutations in the receptor binding domain (RBD) of SARS-CoV-2 may potentially escape the action of the REGN-COV2 cocktail, providing important information for interpreting mutations observed during viral surveillance.

SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Emma S. Winkler et al.

Summary: This study found that neutralizing human monoclonal antibodies in SARS-CoV-2-infected animals require Fc effector functions for optimal protection, reducing inflammation, improving respiratory mechanics, and being associated with diminished immune signaling and tissue repair.

CELL (2021)

Add to Collection

Article Medicine, General & Internal

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: REGEN-COV reduced the risk of Covid-19-related hospitalization or death, resolved symptoms, and reduced the SARS-CoV-2 viral load more rapidly than the placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

P. W. Horby et al.

Summary: Azithromycin has been proposed as a treatment for COVID-19 due to its immunomodulatory actions. However, a study in hospitalized patients with COVID-19 showed that azithromycin did not improve survival or other clinical outcomes. Its use should be restricted to patients with a clear antimicrobial indication.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

SARS- CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study

Maya Moshe et al.

Summary: The study evaluated the performance of new lateral flow immunoassays (LFIAs) for detecting SARS-CoV-2 antibodies in a national COVID-19 seroprevalence program. Seven LFIAs showed sensitivity ranging from 69% to 100% and specificity from 98.6% to 100%. One LFIA was identified with suitable clinical performance for potential inclusion in seroprevalence studies, but none showed superior performance for routine clinical use compared to the current LFIA.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

Alain Townsend et al.

Summary: Serological detection of antibodies against SARS-CoV-2 is crucial to establish seroconversion rates. Researchers have developed a free red cell agglutination test to detect antibodies against the receptor binding domain for distribution to qualified research groups.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Immunology

Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro

Marek Widera et al.

Summary: The study demonstrates that bamlanivimab, casirivimab, and imdevimab can efficiently neutralize authentic SARS-CoV-2, but some variants may be resistant to these monoclonal antibodies.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Rita E. Chen et al.

Summary: Cell culture experiments showed reduced or abrogated neutralizing activity of monoclonal antibodies against SARS-CoV-2 variant strains, but low prophylactic doses of antibody combinations protected against infection in vivo without resistance emergence. Higher doses of several monoclonal antibody cocktails also provided protection against viruses with a B.1.351 spike gene in vivo. Many antibody products with Emergency Use Authorization should therefore retain substantial efficacy against prevailing variant strains of SARS-CoV-2.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

M. P. O'Brien et al.

Summary: The study indicates that subcutaneous REGEN-COV can effectively prevent severe Covid-19 and reduce the duration of symptoms in individuals at high risk for infection due to household exposure to confirmed SARS-CoV-2 cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Virology

Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q

Alexander Wilhelm et al.

Summary: The study found that SARS-CoV-2 variants harboring the L452R substitution had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to the Epsilon variant, both the Kappa and Delta variants showed a greater reduction in neutralization by convalescent sera. Additionally, the Delta variant was resistant to imdemivab but could potentially be overcome with combination therapy involving casirivimab.

VIRUSES-BASEL (2021)

Add to Collection

Article Cell Biology

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Markus Hoffmann et al.

Summary: The emergence of the B.1.617 variant in India may be responsible for the sharp increase in COVID-19 cases and deaths. B.1.617 shows increased efficiency in entering cells and evades antibody responses, contributing to its rapid spread.

CELL REPORTS (2021)

Add to Collection

Article Critical Care Medicine

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Group Author Only

Summary: The study aimed to evaluate the efficacy and safety of colchicine in treating COVID-19 patients, but found that it did not reduce 28-day mortality, hospital stay duration, or risk of progressing to invasive mechanical ventilation or death.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Petra Mlcochova et al.

Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Bin Ju et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Yunlong Cao et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Potently neutralizing and protective human antibodies against SARS-CoV-2

Seth J. Zost et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Johanna Hansen et al.

SCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Peter Horby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Biology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Yiska Weisblum et al.

ELIFE (2020)

Add to Collection

Review Pharmacology & Pharmacy

How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases?

Andreas H. Laustsen

EXPERT OPINION ON DRUG DISCOVERY (2019)

Add to Collection

Article Medicine, General & Internal

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

Sabue Mulangu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

© Peeref 2019-2024. All rights reserved.